Promoted Content
Promoted Content

Find Gastroenterology Drugs in Phase I Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PT101

            Therapeutic Area: Gastroenterology Product Name: PT101

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: $1.9 million Upfront Cash: Undisclosed

            Deal Type: Acquisition February 25, 2021

            Details:

            Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VE202

            Therapeutic Area: Gastroenterology Product Name: VE202

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Financing January 12, 2021

            Details:

            Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SYNB8802

            Therapeutic Area: Gastroenterology Product Name: SYNB8802

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 07, 2020

            Details:

            SYNB8802 is a Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria. Poster titled "In silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria" will be presented at the conference.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BT051

            Therapeutic Area: Gastroenterology Product Name: BT051

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 02, 2020

            Details:

            Single doses of BT051 up to 3500 mg were generally safe and well tolerated in all healthy subjects exposed. Bacainn Therapeutics plans to initiate a Phase 1b clinical trial of BT051 in patients with moderate to severe active ulcerative colitis, based on the study results.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SER-301

            Therapeutic Area: Gastroenterology Product Name: SER-301

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis and induce clinical remission in patients suffering from active UC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SYNB8802

            Therapeutic Area: Gastroenterology Product Name: SYNB8802

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            SYNB8802 is an engineered non-pathogenic strain of E. coli, using Synlogic's Synthetic Biotic platform, designed to consume oxalate in the GI tract and lower urinary oxalate levels, potentially reducing kidney damage due to Enteric Hyperoxaluria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-057

            Therapeutic Area: Gastroenterology Product Name: MORF-057

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 12, 2020

            Details:

            MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).